Related Experiment Video

Updated: Jun 10, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Update on pancreatic cancer treatment

Virginia Sun1

  • 1Department of Population Sciences, City of Hope, Duarte, Calif, USA.

The Nurse Practitioner
|July 21, 2010
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

Related Experiment Videos

Last Updated: Jun 10, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Recruitment strategies for a multisite telehealth trial for rural cancer survivors with ostomies.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Integrating oncology advanced practice providers and clinical pharmacists into clinical cancer research.

Journal of the National Cancer Institute·2026

Social determinants of health in lung cancer surgery: perspectives from family caregivers, clinicians, and healthcare system administrators.

Frontiers in public health·2026

Interrelationship Between Patient and Family Caregiver Outcomes Following Lung Cancer Surgery: A Secondary Analysis of a Randomized Controlled Trial.

Psycho-oncology·2026

Impact of Ostomy Self-Management Telehealth training for rural cancer survivors on health care utilization and economic outcomes in the United States.

The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association·2025

Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned From Qualitative Content Analysis of S1316 - Comparative Effectiveness Trial for Malignant Bowel Obstruction.

The American journal of hospice & palliative care·2025

An emphasis on professionalism for new NP students.

The Nurse practitioner·2026

Utilization of an electronic dashboard to improve health maintenance in veterans with IBD receiving biologic therapy.

The Nurse practitioner·2026

Clinicians' comfort with diagnosing frailty: A review of current perspectives and practices.

The Nurse practitioner·2026

A novel adjunct for COPD: Could it be type II inflammation?

The Nurse practitioner·2026

The Drug Update: Recent drug approvals, summer 2026 edition.

The Nurse practitioner·2026

Idiopathic anaphylaxis and histamine dysregulation: Revisiting pathophysiologic assumptions.

The Nurse practitioner·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us